{"prompt": "['2016N298481 0', 'CONFIDENTIAL', 'GlaxoSmithKline group of companies', '205270', 'TITLE PAGE', 'Protocol Title: A 28-week, randomized, double-blind, placebo-controlled, parallelgroup,', 'multi-center, study in recombinant human erythropoietin (rhEPO) na\u00efve nondialysis', 'participants with anemia associated with chronic kidney disease to evaluate the efficacy,', 'safety and effects on quality of life of daprodustat compared to placebo.', 'Protocol Number: 205270/01', 'Short Title: Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat in', 'Non-Dialysis participants evaluating Hemoglobin and Quality of life (ASCEND-NHQ)', 'Compound Number: GSK1278863', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information:', 'Medical Monitor contact information can be found in the Study Reference Manual.', 'Regulatory Agency Identifying Number(s):', 'IND#: 101291', 'EudraCT: 2017-002270-39', 'Approval Date: 23-AUG-2019', 'Copyright 2019 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited.', '1']['2016N298481_02', 'CONFIDENTIAL', '205270', 'SPONSOR SIGNATORY:', 'PPD', 'PPD', 'Alexander R Cobitz, M.D., Ph.D.', 'Date', 'Executive Director Clinical Development', 'Medicine Delivery Unit', 'GlaxoSmithKline', 'PPD', '2']['2016N298481_02', 'CONFIDENTIAL', '205270', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Protocol Amendment 1', '23-Aug-2019', 'Country Specific Protocol ITA-1', '02-Apr-2018', 'Original Protocol', '22-Aug-2017', 'Amendment Version 1 23-AUG-2019', 'Overall Rationale for Amendment: Amendment conducted to provide clarity regarding', 'follow-up of participants with ADPKD and to incorporate new safety data provided in the', \"Investigator's Brochure.\", 'Section# and Name', 'Description of Change', 'Brief Rationale', 'Section 2: Schedule of', 'Added footnote #17 to state', 'Footnote was added to clarify', 'Activities, Table 1', 'when study treatment should', 'when study treatment is', 'be dispensed.', 'dispensed at study visits', 'through the IRT system.', 'Section 2: Schedule of', 'Revised footnote #9 to permit a', 'A re-test provides an', 'Activities, Table 1', 'HemoCue Hgb retest with a', 'opportunity for participants and', 'new blood sample', 'sites to avoid the inappropriate', 'screen-failures due to technical', 'issues with the initial sample', 'collection and analysis via the', 'HemoCue device.', 'Section 2: Schedule of', 'Revised footnote #12 to clarify', 'To clarify the purpose of the', 'Activities, Table 1', 'the purpose of the participant', 'participant reminder card.', 'reminder card', 'Section 2: Schedule of', 'Edited footnote #15 to add', 'All participants with ADPKD', 'Activities, Table 1', 'necessary ultrasound', 'will require an ultrasound', 'assessments for ADPKD', 'within one month of study', 'participants at end of treatment', 'treatment discontinuation or as', 'soon as clinically feasible as', 'mandated by Dear Investigator', 'Letter (DIL, dated 14 Dec', '2018)', 'Section 2: Schedule of', 'Added row to conduct', 'Clarified timepoints for', 'Activities for Patient Reported', 'assessment regarding', 'collection of the healthcare', 'Outcomes and Actigraphy,', 'healthcare resource utilization', 'resource utilization data for all', '3']\n\n###\n\n", "completion": "END"}